The difference in mean costs as a pharmacoeconomic outcome variable: power considerations

Area of Science:

• Health economics
• Pharmacoeconomics
• Clinical trial analysis

Background:

• Pharmacoeconomic evaluations are crucial for assessing the value of new drugs.
• Determining cost differences between treatment groups is a key component.
• Understanding cost distributions is essential for robust analysis.

Purpose of the Study:

• To establish a method for pharmacoeconomic evaluation of a new drug.
• To determine the distribution of costs without treatment using hospital records.
• To simulate sampling properties and establish significance break points for cost differences.

Main Methods:

• Utilizing hospital records to define the cost distribution under the null hypothesis (no treatment).
• Employing simulation techniques to establish sampling properties.
• Generating the cost distribution under the alternative hypothesis (drug treatment) using clinical hypotheses.
• Calculating a break point of cost differences corresponding to a specified significance level.

Main Results:

• The simulation results provide a method to determine a critical difference in costs for statistical significance.
• This approach allows for the determination of power for clinical hypotheses.
• A framework is established for comparing treatment costs in pharmacoeconomic studies.

Conclusions:

• The study presents a simulation-based approach for pharmacoeconomic evaluation.
• This method aids in determining the statistical significance of cost differences between drug and placebo groups.
• The findings support robust cost-effectiveness analysis for new pharmaceutical interventions.